The following is a summary of “A systematic review and meta-analysis of the response to placebo in clinical trials of ...

Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced that the ...

When you buy through links on our articles, Future and its syndication partners may earn a commission.

Gwyneth Paltrow spoke to Vanity Fair as part of a new cover story and pulled back the curtain a bit on her big return to ...

Inclusion body myositis (IBM) is an inflammatory myopathy causing proximal and distal muscle weakness. IBM’s cause remains ...

“They’re not going anywhere.” Krukow has inclusion body myositis, known as IBM, a degenerative disease that weakens muscles over time. He has been especially grateful that the Giants bought ...

US-based biotech Abcuro has raised $200m to advance the development of its monoclonal antibody ulviprubart in the rare muscle disease called inclusion body myositis (IBM). The funding round ...

potentially highlighting a distinct inclusion body myositis subtype with a more severe phenotype. Pooled IBM case data from four European countries were used. Researchers based in Nijmegen, The ...

and inclusion body myositis (IBM). Myositis-specific autoantibodies define different subtypes of myositis. For example, patients with anti-Mi2 autoantibodies targeting the chromodomain helicase ...